GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (OTCPK:AVCTF) » Definitions » Notes Receivable

AVCTF (Avacta Group) Notes Receivable : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Avacta Group Notes Receivable?

Avacta Group's Notes Receivable for the quarter that ended in Jun. 2024 was $0.00 Mil.


Avacta Group Notes Receivable Historical Data

The historical data trend for Avacta Group's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Notes Receivable Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avacta Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Avacta Group Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Avacta Group Notes Receivable Related Terms

Thank you for viewing the detailed overview of Avacta Group's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group Headlines

From GuruFocus

Avacta's Diagnostic Division Achieves ISO 13485 Certification

By Business Wire Business Wire 07-14-2021

Avacta Expands Rapid SARS-CoV-2 Antigen Test Manufacturing Capacity

By Business Wire Business Wire 09-02-2020

First Patient Dosed in the US in Avacta's AVA6000 Phase 1 Clinical Study

By Business Wire Business Wire 04-27-2023

Avacta Group plc Signs License Agreement With Astrea Bioseparations

By Business Wire Business Wire 12-21-2020

Avacta Appoints Dr Christina Coughlin as Non-Executive Director

By Business Wire Business Wire 03-21-2022

Avacta Launches SARS-CoV-2 BAMS Research Test

By Business Wire Business Wire 09-30-2020

Avacta Submits Clinical Trial Application for AVA6000 pro-doxorubixin

By Business Wire Business Wire 12-23-2020